Pfizer joins Minnesota and Company to discuss how to protect yourself by scheduling your vaccines to prevent serious consequences.

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Pfizer shares were rising early Tuesday after the company reported fourth-quarter earnings and revenue that came in ahead of ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Drugmaker pauses HPV Gardasil exports as rival Pfizer gets boost from better than expected Covid vaccine and pill sales ...

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...